| Dr Lucas Matthew Drake, MD | |
|
8051 South Emerson Ave, Indianapolis, IN 46237-8632 | |
| (317) 865-2955 | |
| (317) 865-2944 |
| Full Name | Dr Lucas Matthew Drake |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 19 Years |
| Location | 8051 South Emerson Ave, Indianapolis, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629152152 | NPI | - | NPPES |
| 201023420 | Medicaid | IN | |
| M400049541 | Other | IN | MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 01069652A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Franciscan Health Indianapolis | Indianapolis, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Indianapolis Gastroenterology Llc | 0244201432 | 17 |
News Archive
In a breach of patient trust, a British hospital shared the personal information of around 1.6 million patients with Google's DeepMind. This was reported by a British data protection watchdog - Information Commissioner's Office (ICO) yesterday, creating a stir. The deal between the Royal Free NHS Trust and Google's DeepMind first became known to the public in February 2016.
A Kids' Brain Tumor Cure Foundation, Solving Kids' Cancer and the Ty Louis Campbell Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors.
Pharmacyclics, Inc. today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma or diffuse large B-cell lymphoma.
ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).
For the millions of people every year who have or need medical devices implanted, a new advancement in 3D printing technology developed at the University of Florida promises significantly quicker implantation of devices that are stronger, less expensive, more flexible and more comfortable than anything currently available.
› Verified 6 days ago
| Entity Name | Indianapolis Gastroenterology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518964493 PECOS PAC ID: 0244201432 Enrollment ID: O20040802001561 |
News Archive
In a breach of patient trust, a British hospital shared the personal information of around 1.6 million patients with Google's DeepMind. This was reported by a British data protection watchdog - Information Commissioner's Office (ICO) yesterday, creating a stir. The deal between the Royal Free NHS Trust and Google's DeepMind first became known to the public in February 2016.
A Kids' Brain Tumor Cure Foundation, Solving Kids' Cancer and the Ty Louis Campbell Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors.
Pharmacyclics, Inc. today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma or diffuse large B-cell lymphoma.
ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).
For the millions of people every year who have or need medical devices implanted, a new advancement in 3D printing technology developed at the University of Florida promises significantly quicker implantation of devices that are stronger, less expensive, more flexible and more comfortable than anything currently available.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lucas Matthew Drake, MD 8051 South Emerson Ave, Suite 200, Indianapolis, IN 46237-8632 Ph: (317) 865-2955 | Dr Lucas Matthew Drake, MD 8051 South Emerson Ave, Indianapolis, IN 46237-8632 Ph: (317) 865-2955 |
News Archive
In a breach of patient trust, a British hospital shared the personal information of around 1.6 million patients with Google's DeepMind. This was reported by a British data protection watchdog - Information Commissioner's Office (ICO) yesterday, creating a stir. The deal between the Royal Free NHS Trust and Google's DeepMind first became known to the public in February 2016.
A Kids' Brain Tumor Cure Foundation, Solving Kids' Cancer and the Ty Louis Campbell Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors.
Pharmacyclics, Inc. today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma or diffuse large B-cell lymphoma.
ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).
For the millions of people every year who have or need medical devices implanted, a new advancement in 3D printing technology developed at the University of Florida promises significantly quicker implantation of devices that are stronger, less expensive, more flexible and more comfortable than anything currently available.
› Verified 6 days ago
Irene A Carrothers, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1701 Senate Blvd, Indianapolis, IN 46202 Phone: 317-963-8776 Fax: 317-963-5285 | |
Liam P Howley, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1001 West 10th St Opw-m200, Indiana University Department Of Medicine, Indianapolis, IN 46202 Phone: 317-630-6560 | |
Cristina Nancy Perez Chumbiauca, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 550 University Blvd, Indianapolis, IN 46202 Phone: 317-944-5000 | |
Dr. Andrew Jonathen Ortega, DO Gastroenterology Medicare: Medicare Enrolled Practice Location: 702 Rotary Cir, Indianapolis, IN 46202 Phone: 317-278-4427 | |
Lawrence John Born, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 8424 Naab Rd, #3-j, Indianapolis, IN 46260 Phone: 317-872-7396 Fax: 317-879-8328 | |
Brian T Robinson, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1001 W 10th St, Indianapolis, IN 46202 Phone: 317-630-7979 Fax: 317-630-2668 | |
Steven T Hugenberg, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 550 University Blvd, Indianapolis, IN 46202 Phone: 317-944-8660 |